Abivax (ABVX) Equity Average (2025 - 2026)
Abivax (ABVX) recorded quarterly Equity Average of $516.4 million in Q1 2026, down 8.4% quarter-over-quarter from $563.8 million in Q4 2025, and up 2733.46% on a YoY basis from $18.2 million in Q1 2025.
Abivax (ABVX) Equity Average (2025 - 2026) Analysis & Trends
Abivax's Equity Average history runs 2 years deep, the most recent figure standing at $516.4 million for Q1 2026.
- In Q1 2026, Equity Average rose 2733.46% year-over-year to $516.4 million; the TTM figure through Mar 2026 stood at $516.4 million (up 2733.46% YoY), while the FY2025 annual figure was $286.6 million, up 125.45% from the prior year.
- Equity Average was $516.4 million for Q1 2026 at Abivax, down from $563.8 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $563.8 million in Q4 2025 to a low of -$30.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 3.50 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 783.14 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.76 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.01 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 21.35 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 19.01 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 516.41 Mn |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 31.34 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 516.41 Mn |
| Dec 31, 2025 | 563.77 Mn |
| Sep 30, 2025 | 271.51 Mn |
| Jun 30, 2025 | -30.79 Mn |
| Mar 31, 2025 | 18.23 Mn |